Ind-Swift Laboratories Share Price

Name: Ind-Swift Laboratories
Brand: Ind-Swift Laboratories

Small Cap

₹112.64

-0.64 (-0.56%)

15 October, 2024 08:41 BSE: 532305 NSE: INDSWFTLAB ISIN: INE915B01019

Start SIP in Ind-Swift Laboratories

Start SIP

Ind-Swift Laboratories Performance

Day Range

Low 110
High 115

₹ 112

52 Week Range

Low 82
High 186

₹ 112

Open Price113
Previous Close113
Volume80324

Ind-Swift Laboratories Chart

Over 1 Month -21.77%
Over 3 Month -16.27%
Over 6 Month -13.32%
Over 1 Year + 21.12%

Ind-Swift Laboratories Key Statistics

P/E Ratio	2.3
PEG Ratio	0
Market Cap Cr	666
Price to Book Ratio	0.7
EPS	23.3
Dividend	0
Relative Strength Index	22.51
Money Flow Index	5.66
MACD Signal	-6.17
Average True Range	6.2

Ind-Swift Laboratories Investment Rating

Master Rating:
Ind-Swift Labs. (Nse) has an operating revenue of Rs. 1,003.73 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 45% is great, ROE of 45% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 22 which is a POOR score indicating inconsistency in earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Ind-Swift Laboratories Financials

Standalone Consolidated

Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios
Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios

Indicator	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Oper Rev Qtr Cr	30	382	276	270	299	290
Operating Expenses Qtr Cr	35	309	222	207	239	234
Operating Profit Qtr Cr	-5	73	54	63	60	56
Depreciation Qtr Cr	0	13	14	13	14	9
Interest Qtr Cr	0	-11	21	21	20	22
Tax Qtr Cr	0	134	5	6	14	39
Net Profit Qtr Cr	6	350	22	30	17	-31

Indicator	Mar 2024	Mar 2023
Total Revenue Annual Cr	1,273	1,185
Operating Expenses Annual Cr	977	930
Operating Profit Annual in Cr	250	222
Depreciation Cr	53	57
Interest Annual Cr	51	92
Tax Annual Cr	159	37
Net Profit Annual Cr	418	42

Indicator	Mar 2024	Mar 2023
Cash from Operating Activity Annual Cr	-180	183
Cash from Investing Activity Annual Cr	-104	-14
Cash from Financing Annual Activity Cr	700	-168
Net Cash Flow Annual Cr	416	1

Indicator	Mar 2024	Mar 2023
Total ShareHolders Funds Annual Cr	922	675
Fixed Assets Annual Cr	8	595
Total Non Current Assets Annual Cr	559	714
Total Current Assets Annual Cr	546	1,074
Total Assets Annual Cr	1,105	1,788

Indicator	Mar 2024	Mar 2023
Book Value Per Share Annual Rs	156	113
ROE Annual %	45	9
ROCE Annual %	26	14
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	24	22

Indicator	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Oper Rev Qtr Cr	33	393	288	290	310	304
Operating Expenses Qtr Cr	43	431	236	224	250	240
Operating Profit Qtr Cr	-10	-37	51	66	60	65
Depreciation Qtr Cr	0	13	14	13	14	9
Interest Qtr Cr	0	-11	21	21	20	22
Tax Qtr Cr	0	134	4	7	14	41
Net Profit Qtr Cr	1	239	19	32	17	-24

Indicator	Mar 2024	Mar 2023
Total Revenue Annual Cr	1,326	1,241
Operating Expenses Annual Cr	1,027	978
Operating Profit Annual in Cr	254	229
Depreciation Cr	53	57
Interest Annual Cr	51	92
Tax Annual Cr	160	39
Net Profit Annual Cr	421	48

Indicator	Mar 2024	Mar 2023
Cash from Operating Activity Annual Cr	-181	195
Cash from Investing Activity Annual Cr	-104	-13
Cash from Financing Annual Activity Cr	699	-186
Net Cash Flow Annual Cr	414	-4

Indicator	Mar 2024	Mar 2023
Total ShareHolders Funds Annual Cr	931	682
Fixed Assets Annual Cr	8	595
Total Non Current Assets Annual Cr	504	660
Total Current Assets Annual Cr	661	1,165
Total Assets Annual Cr	1,165	1,824

Indicator	Mar 2024	Mar 2023
Book Value Per Share Annual Rs	158	114
ROE Annual %	45	10
ROCE Annual %	26	14
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	23	22

Invest in Ind-Swift Laboratories

Ind-Swift Laboratories Technicals

EMA & SMA

Current Price

₹112.64

-0.64 (-0.56%)

Bullish Moving Average
___
0

Bearish Moving Average
___
16

EMA SMA

20 Day
₹126.12

50 Day
₹133.50

100 Day
₹131.64

200 Day
₹122.30

20 Day
₹127.81

50 Day
₹141.75

100 Day
₹132.96

200 Day
₹121.37

Ind-Swift Laboratories Resistance and Support

PIVOT

₹112.6

Resistance
First Resistance	115.49
Second Resistance	118.35
Third Resistance	121.24

RSI	22.51
MFI	5.66
MACD Single Line	-6.17
MACD	-7.67

Support
First Support	109.74
Second Support	106.85
Third Supoort	103.99

Ind-Swift Laboratories Delivery and Volume

Period	NSE + BSE Volume Avg	NSE + BSE Delivery Volume Avg	NSE + BSE Delivery Volume %
Day	87,748	8,774,800	100
Week	108,667	10,866,660	100
1 Month	78,776	7,877,635	100
6 Month	759,280	34,904,106	45.97

Ind-Swift Laboratories Result Highlights

Ind-Swift Laboratories Synopsis

NSE-Medical-Generic Drugs

Ind-Swift Laboratori is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1151.96 Cr. and Equity Capital is Rs. 59.81 Cr. for the Year ended 31/03/2023. Ind-Swift Laboratories Ltd. is a Public Limited Listed company incorporated on 04/01/1995 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1995PLC015553 and registration number is 015553.

Market Cap	666
Sales	959
Shares in Float	3.43
No of funds	12
Yield

Book Value	0.72
U/D Vol ratio	0.8
LTDebt / Equity	151
Alpha
Beta	1.07

Ind-Swift Laboratories Shareholding Pattern

Owner Name	Jun-24	Mar-24	Dec-23
Promoters	42%	42%	42%
Foreign Portfolio Investors	1.27%	0.26%	0.31%
Individual Investors	36.69%	30.46%	29.27%
Others	20.04%	27.28%	28.42%

Ind-Swift Laboratories Management

Name	Designation
Mr. Navrattan Munjal	Chairman & Managing Director
Mr. Himanshu Jain	Joint Managing Director
Mr. Rishav Mehta	Executive Director
Mr. Sahil Munjal	Executive Director
Dr. Ashwani Kumar Vig	Independent Director
Mr. Rajinder Kumar Gupta	Independent Director
Mr. S P Sharma	Independent Director
Ms. Neerja Chathley	Independent Woman Director

Ind-Swift Laboratories Forecast

Price Estimates

2,000(9.8%)

1,758(-3.5%)

1,590(-12.7%)

Other Analyst Rating

Ind-Swift Laboratories Corporate Action

Board

Date	Purpose	Remarks
2024-08-12	Quarterly Results
2024-06-27	Preferential issue of shares
2024-05-13	Audited Results
2024-02-12	Quarterly Results
2023-11-07	Quarterly Results

Ind-Swift Laboratories FAQs

What is Share Price of Ind-Swift Laboratories ?

Ind-Swift Laboratories share price is ₹112 As on 15 October, 2024 | 08:27

What is the Market Cap of Ind-Swift Laboratories ?

The Market Cap of Ind-Swift Laboratories is ₹665.6 Cr As on 15 October, 2024 | 08:27

What is the P/E ratio of Ind-Swift Laboratories ?

The P/E ratio of Ind-Swift Laboratories is 2.3 As on 15 October, 2024 | 08:27

What is the PB ratio of Ind-Swift Laboratories ?

The PB ratio of Ind-Swift Laboratories is 0.7 As on 15 October, 2024 | 08:27

Ind-Swift Laboratories Key Statistics

P/E Ratio	2.3
PEG Ratio	0
Market Cap Cr	666
Price to Book Ratio	0.7
EPS	23.3
Dividend	0
Relative Strength Index	22.51
Money Flow Index	5.66
MACD Signal	-6.17
Average True Range	6.2

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.